Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Among the trends in the report are a growing proportion of younger adults with HF and worsening of racial disparities.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market ...

The findings were particularly pronounced in individuals with dementia, pointing to a possible vascular benefit of higher BP.

With patients surviving longer, there is a need to address long-term risks of CVD associated with cancer, say experts.

We've been talking about it for decades, but we haven't seen the progress that we really want to see,” Vijay Kunadian says.

The society says it is discussing virtual options to deliver the educational content to attendees at a later date.